Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
SANUWAVE Health, Inc. reports company developments tied to FDA-cleared and FDA-approved directed-energy systems used in advanced wound care. The company researches, develops and commercializes non-invasive regenerative medicine technologies designed to activate biological responses for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its wound care portfolio includes the UltraMIST product line and related product candidates.
Recurring news includes quarterly and annual revenue updates, financial guidance, conference-call materials, medical-device commercialization activity and channel relationships for UltraMIST. Company updates also describe applications of its energy transfer technologies in wound healing, orthopedic and spine, aesthetic and cosmetic, and cardiac and endovascular conditions.
Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.
The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.
Full Q2 2025 results will be released around August 8th, 2025.
Sanuwave Health (NASDAQ: SNWV), a provider of non-invasive wound care solutions, has been selected for inclusion in the Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30. The company will also be included in the broader Russell 3000® Index and Russell Microcap® Index.
The Russell indexes, which capture the 4,000 largest U.S. stocks by market capitalization, are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked to these indexes as of June 2024. Membership in these indexes remains in place for one year.
Sanuwave Health specializes in regenerative medicine products for wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions through their patented energy transfer technologies.
Sanuwave Health (NASDAQ:SNWV) has appointed Greg Bazar to its Board of Directors. Bazar brings extensive experience in engineering, computer science, cybersecurity, AI, and business intelligence. He currently serves as Chairman of Simpatico Systems and was previously instrumental at 3D-P, leading to its acquisition by Epiroc. The appointment comes as board member Michael Stolarski steps down, though he will remain as a consultant to assist with the transition.
Bazar's appointment aligns with Sanuwave's focus on interdisciplinary leadership and its evolution beyond therapeutics into informational ecosystems. His background in technology and cybersecurity is expected to contribute to the company's future roadmap in wound care solutions.
Sanuwave Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss their Q1 2025 financial results on Friday, May 9, 2025, at 8:30 AM ET.
Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Materials will be available on the company's investor website, and a replay will be accessible until May 30, 2025, using the replay access ID: 11158734.
SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.
The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.
The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.
SANUWAVE Health (NASDAQ: SNWV) reported record-breaking financial results for Q4 and full year 2024. Q4 revenues reached $10.3 million, up 47% year-over-year, with a gross margin of 77.9%. Full-year 2024 revenues hit $32.6 million, increasing 60% from 2023.
Key Q4 highlights include:
- 135 UltraMist® systems sold (up from 79 in Q4 2023)
- UltraMist® consumables revenue grew 59% to $5.9 million
- Operating income of $2.5 million, up 143%
- Adjusted EBITDA of $3.7 million
For 2025, SANUWAVE projects Q1 revenue of $8.4-9.0 million (45-55% YoY growth) and full-year revenue guidance of $48-50 million (47-53% growth). The company completed a 1-for-375 reverse stock split and raised $10.3 million through private placement in Q4 2024.
SANUWAVE Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss its Q4 and Full Year 2024 financial results. The call will take place on March 21, 2025, at 8:30 AM ET.
Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Supporting materials will be available on the company's investor relations website. A replay of the call will be accessible through April 11, 2025, using the replay access ID: 11157832.
Sanuwave Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, has announced its approval for listing on the Nasdaq Global Market. The company's common stock will begin trading on Nasdaq on March 7, 2025, maintaining its current ticker symbol 'SNWV'.
The transition from OTCQB to Nasdaq represents a significant milestone for Sanuwave after 18 months of transition and progress. Stockholders are not required to take any action regarding the uplisting. CEO Morgan Frank expressed enthusiasm about joining one of the world's premier stock exchanges, highlighting the company's goal of transforming the wound care market and creating shareholder value.